Findings: WEIGHT LOSS IN ADOLESCENTS The STEP TEENS study detailed below evaluated the effects of Wegovy on weight loss in obese adolescents aged 12 - 17 years RCT STEP TEENS Study - Wegovy vs Placebo for Weight Loss in Obese Adolescents, NEJM (2022) [PubMed abstract] The STEP TEENS study enrolled 201 obese adolescents aged 12 - 17 years Main inclusion criteria Age 12 to 10% Baseline characteristics Average age 15.4 years Female sex - 62% Average weight - 238 lbs (108 kg) Average BMI - 37 Randomized treatment groups Group 1 (134 patients): Wegovy 2.4 mg once weekly Group 2 (67 patients): Placebo Before treatment, all patients underwent a 12-week run-in phase where they received lifestyle interventions Wegovy was started at 0.25 mg once weekly and titrated to 2.4 mg over 16 weeks Percentage change in BMI from baseline to week 68 Primary outcome: Results Among adolescents with obesity, once-weekly treatment with a 2.4-mg dose of semaglutide plus lifestyle intervention resulted in a greater reduction in BMI than lifestyle intervention alone Findings: Summary Wegovy caused impressive weight loss in the STEP TEENS study, and its effects were greater than other drugs approved for adolescent obesity (see Qsymia and Saxenda)
In the last decades, IGF-1 has been implicated in many physiological actions, among others: tissue growth and development, proliferative, lipid metabolism, pro-survival/anti-aging, anti-inflammatory, anabolic, and antioxidant with neuro- and hepatoprotective properties [105116]
Ballet History through a Queer Lens Category: Oral Presentation Author(s): Oliver Myers Presenter(s): Oliver Myers Mentors(s): Leah Holz My Honors Thesis explores ballet history with a focus on queer themes, culture, and figures
Some blood banks may ask whether your GLP-1 medication is for diabetes management or weight loss, as this can inform their assessment of your overall metabolic health
In synucleinopathies, EGCG enhances alpha-synuclein clearance and protects mitochondrial function
2026 BacteriostaticWaterLab.com
